My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
Gives rise to the superior laryngeal nerve (SLN) and recurrent laryngeal nerve (RLN) in the neck
After descending toward the larynx:
The SLN divides into:
The internal laryngeal nerve (ILN)
External laryngeal nerve (ELN)
The RLN innervates all of the intrinsic muscles of the larynx:
Except the cricothyroid muscle:
This muscle, tenses the vocal cords and adducts the vocal cords:
Is innervated by the ELN
The other branch of the SLN, the ILN:
Provides sensory innervation to the laryngeal mucosa
There are many exceptions to the normal innervation of the laryngeal muscles:
Which can influence the interpretation of laryngoscopy results or voice changes after thyroid surgery
A neural anastomosis:
That provides additional motor innervation to the muscles of the larynx normally innervated by the injured nerve:
Can contribute to an incorrect interpretation of injury during laryngoscopy or stroboscopy
According to recent clinical studies:
Electrical stimulation of the RLN can cause contraction of the cricothyroid muscle:
This suggests that extra-laryngeal branches and or other communications of the RLN:
Can sometimes contribute to innervation of this muscle
The laryngeal nerves:
Can form a great variety of anastomoses:
These various connections among the ILN, ELN, and RLN have been investigated by many anatomists over the centuries
Claudius Galen:
Was the first to describe the communication between the ILN and RLN
Currently, Galen’s anastomosis:
Is most commonly defined as:
The direct communication between the posterior branches of the ILN and the RLN
It can occur as:
A single trunk
A double trunk
A plexus
Besides Galen’s anastomosis, other communications have been observed and described as follows:
The arytenoid plexus:
Which links the anterior branch of the RLN with the arytenoid branch of the ILN
The arytenoid plexus and the cricoid communication. AP, arytenoid plexus; CA, cricoid communication; ILN, internal laryngeal nerve; RLN, recurrent laryngeal nerve (a, anterior; p, posterior).
The cricoid communication:
Which connects branches originating bilaterally from the RLNs with the superior branch from the deep portion of the arytenoid plexus
The thyroarythenoid communication:
Which is formed by the ascending branch of the RLN and the descending branch from the anterior branch of the ILN
The thyroarytenoid communication and the communication between the external laryngeal nerve (ELN) and the recurrent laryngeal nerve (RLN). CN, communicating nerve; ILN, internal laryngeal nerve; TAC, thyroarytenoid communication
The communication between the ELN and RLN:
Human communicating nerve
The communication between the ILN and ELN
The communication between the RLN and the sympathetic trunk
Communications between the internal laryngeal nerve (ILN) and the external laryngeal nerve (ELN) and between the recurrent laryngeal nerve (RLN) and the sympathetic trunk. SLN, superior laryngeal nerve; TF, thyroid foramen.
Despite progress in the development of new techniques:
Such as intra-operative nerve monitoring:
Which help to reduce the risk of iatrogenic injuries during thyroid surgeries and other procedures conducted in close proximity to the laryngeal nerves:
The laryngeal muscles are often paralyzed postoperatively due to iatrogenic injury to the laryngeal nerves
In view of the complexity and variability of the anatomy in this region:
Detailed anatomical knowledge is crucial if surgery is to be both successful and safe, and to reduce the risk of nerve injury
Observing an intra-laryngeal anastomosis during laryngeal surgery or an extra-laryngeal communication between laryngeal nerves during thyroid surgery:
Can lead to confusion, misidentification, and an increased risk of iatrogenic injury
A thorough understanding of the complex anastomoses between the laryngeal nerves is crucial in patients with laryngeal muscle paralysis
Paralyzed laryngeal muscles can be spontaneously reinnervated from an anastomosis between laryngeal nerves
Additionally, in cases in which surgical reinnervation is required, some of the nerves that form anastomoses can be used as grafts to restore damaged nerve connections
On the other hand, variations in the normal anatomy of the laryngeal nerves can disrupt selective surgical laryngeal reinnervation:
A procedure based on the assumption that each laryngeal muscle is supplied by only one nerve branch originating from the RLN
Anastomoses among laryngeal nerves can result in exceptions to this rule
Such anastomoses have been widely described in the literature:
However, there is still no consensus about their prevalence and functionality
The significant heterogeneity among studies reporting data on anastomoses between the laryngeal nerves is noteworthy:
For example, the reported prevalence of the most common communication, Galen’ s anastomosis:
Ranges from 25% to 100%
Prevalence of Galen’s anastomosis:
A total of 14 studies (n = 890 hemilarynges) presented data on the prevalence of Galen’s anastomosis
The overall pooled prevalence rate:
Was 76.7% (95% confidence interval [CI]: 59.0– 90.0)
Subgroup analysis revealed no significant difference in the prevalence of Galen’s anastomosis between the right and left sides
Subgroup analyses by gender (males vs females) and geographical origin, and the sensitivity analysis, also revealed no significant differences:
However, although the difference was not significant:
The prevalence of the anastomosis was highest in Europeans (88.2%) and lowest in North Americans (44.8%)
Analysis of the different types of Galen’s anastomosis (two studies, n = 261 anastomoses):
Showed a significant difference in the prevalence between single versus double trunk and plexus formation
But no significant difference between double trunk and plexus formation
The most common type of Galen’s anastomosis was a single trunk:
With a pooled prevalence rate 92.3% (95% CI: 84.1–97.5)
This was followed by the double trunk anastomosis type:
With a pooled prevalence of 4.2% (95% CI: 0.5– 10.7)
The plexus formation type with a pooled prevalence of 3.5% (95% CI: 0.2–9.5) (I2: 70.4%, 95% CI: 0–93.3; Co- chran’s Q, P value = 0.066
Prevalence of a communication between the ELN and RLN
A total of eight studies (n = 639 hemilarynges) provided data on the prevalence of the communication between the ELN and RLN
The overall meta-analysis revealed that this communication was present in:
21.3% of hemilarynges (95% CI: 3.8–46.0)
A subgroup analysis showed no significant difference between left and right sides
Although the difference was not statistically significant:
The pooled prevalence rate calculated for the North American subgroup (32.0%) was twice that for the European subgroup (14.4%)
Prevalence of the arytenoid plexus:
Five studies (n = 478 hemilarynges) included data on the prevalence of the arytenoid plexus:
The pooled prevalence rate was 79.7% (95% CI: 41.1–100)
In the European subgroup:
The arytenoid plexus was observed in 96.9% of hemilarynges (95% CI: 83.6–100)
Subgroup analysis revealed no significant difference with respect to side
Prevalence of the cricoid communication:
Two studies (n = 120 hemilarynges) reported prevalence data for the cricoid communication:
The pooled prevalence rate was 19.7% (95% CI: 0–100)
There was no significant difference in sub- group analysis based on side
Prevalence of the thyroarytenoid communication:
A total of three studies (n = 430 hemilarynges) presented data on the prevalence of the thyroarytenoid communication:
The overall pooled prevalence was 6.3% (95% CI: 0.4–16.9)
In subgroup analysis, there was no significant difference in pooled prevalence between the right and left sides:
The calculated pooled rate for the left side (15.9%) was almost twice that for the right side (8.8%)
Communication between the ILN and ELN:
A total of two studies (n = 280 hemilarynges) reported data on a communication between the ILN and ELN
The pooled prevalence estimate of this communication in hemilarynges was 8.8% (95% CI: 0–35.3; I2 97.0%, 95% CI: 92.2–98.8; Cochran’s Q, P value <0.001)
In 1984 Göran Åkerström, on the basis of 503 necropsies, analysed the location of the parathyroid glands:
Together with the work of Gilmour (n=478) and Wang (n=160), they form the foundations of our current knowledge on the subject
Dr. Juan M. Rangone modified the diagrams from Åkerström’s original publication to come up with the percentages of location of the “normodescended” parathyroid glands:
A. Percentages of the different locations of the superior parathyroid glands:
80% corresponds to the midglandular variant
12% to the cricopharyngeal variant
Usually located 1 cm higher than the crossing of the recurrent laryngeal nerve and the inferior thyroid artery
B. Percentages of the different locations of the inferior parathyroid glands:
Roughly 90% are located at the level, or no more than 1 cm below the inferior pole of the thyroid gland
The lower and lateral retraction of the upper thyroid pole:
Reveals a diamond-shaped avascular space
The area is limited:
Medially:
By the lamina of the thyroid cartilage (superiorly) and cricoid cartilage (inferiorly):
Both covered by the cricothyroid muscle
Inferolaterally:
The space is circumscribed by the medial border of the upper thyroid pole and the upper border of the thyroid isthmus
The “roof” of the area:
Is covered by 2 or 3 “bridging” blood vessels that must be controlled to access the space
The “opening” of this virtual space:
Prior to the ligature of the upper thyroid pedicle:
Is a safety maneuver to protect the external branch of the superior laryngeal nerve
Landmarks:
Thyroid cartilage
Reeve cricothyroid space
Space with “bridging” blood vessels
Upper thyroid pole
Cricothyroid muscle
External branch of the superior larngeal nerve
Superior thyroid artery
Superior thyroid vein
Reference:
Abdullah H, Bliss R, Reeve T, Delbridge L (2000) Recognition of the avascular space medial to the upper pole of the thyroid and its surgical implications. Asian J. Surg. 23: 86–9.
👉The external branch of the superior laryngeal nerve (EBSLN) has been labelled ‘the neglected nerve’ of thyroid surgery.
👉Most surgeons have simply attempted to avoid this nerve on the assumption that so doing will prevent injury; however, it is now recognized that injury is relatively common and associated with the potential for significant impairment, espe- cially for those who use their voices professionally.
👉I was taught to always attempt to identify the nerve and recommend doing so.
👉Recently Aina and Hisham have shown that the nerve can be routinely identified in over 90% of cases, a level that sets a new benchmark for head and neck surgeons / endocrine surgeons.
👉The key to identifying the nerve is to develop the avascular plane between the cricothyroid muscle and the medial border of the upper pole of the thyroid lobe, a manoeuvre facilitated by lateral retraction of the lobe.
👉Awareness of the various positions of the EBSLN according to the Cernea classification is also essential if the nerve is to be both identified and preserved.
👉Type 1 EBSLN are located well clear of the thyroid, more than 1 cm above the upper pole of the lobe passing directly into the cricothyroid muscle.
👉Type 2a nerves pass in the vicinity of the superior thyroid vessels as they enter the gland substance.
👉Type 2b nerves cross over the anterior surface of the thyroid lobe.
👉Awareness of the anatomic variations, such as the nerve of Galen, a direct communication between the RLN and EBSLN, is important in avoiding injury to the nerve.
The true prevalence of iatrogenic injury to the EBSLN during thyroid surgery remains difficult to quantify, largely due to underdiagnosis and variability in clinical presentation.
– The pathophysiology and anatomical risk stratification of EBSLN injury were elegantly described by Cernea et al. in 1992 [1]. In this landmark study, the variant in which the nerve crosses the superior thyroid pedicle below the plane of the upper pole apex—classified as Cernea type 2B—was identified as carrying a high risk of injury.
– Although this configuration was initially reported in approximately 14% of cadaveric dissections by the University of São Paulo group [1], later clinical series by Gianlorenzo Dionigi et al. demonstrated that this “high-risk” anatomy may be present in up to 54% of patients with large or bulky goiters [2], significantly increasing surgical complexity.
– First popularized by Mossman and DeWeese (1968), Joll’s sterno-thyro-laryngeal triangle remains a valuable anatomical landmark for identifying the EBSLN during superior pole dissection [3].
– In 1986, Michael Friedman provided a detailed description of the surgical approach to the upper thyroid pole that many of us continue to employ in complex cases, particularly when exposure of the EBSLN is critical [4].
– At the supero-external angle of the intermuscular pocket, created to identify the insertion of the sternothyroid muscle on the oblique line of the thyroid cartilage, surgeons frequently encounter a small arterial vessel. While its injury usually causes only minor (though often annoying) bleeding, it serves as an important anatomical landmark.
– These vessels supply the upper portion of the sternohyoid muscle, above the level of the cricoid cartilage.
– According to Wang et al. [5], in approximately 75% of cases, this vessel represents a terminal branch of a common trunk with the cricothyroid artery, originating from the superior thyroid artery. Before bifurcation, this trunk also gives rise to small nourishing branches to the thyrohyoid and omohyoid muscles.
– The so-called “sternohyoid nutrient vessel” is anatomically unique in 56% of cases [5]. After emerging superficially, it enters the (virtual) intermuscular space between the posterior surface of the sternohyoid and the anterior surface of the sternothyroid muscle, following one of two patterns:
✅ coursing along (“hugging”) the lateral border of the sternothyroid muscle, or ✅ directly piercing the most cranial fibers of the sternothyroid muscle.
– Awareness of this vascular anatomy can facilitate safe superior pole dissection, improve EBSLN identification, and ultimately reduce the risk of voice-related complications following thyroid surgery.
References
Cernea CR, et al. Identification of the external branch of the superior laryngeal nerve during thyroidectomy. Am J Surg. 1992. Dionigi G, et al. Surgical anatomy of the external branch of the superior laryngeal nerve. Gland Surg. Mossman HW, DeWeese MS. The surgical anatomy of the larynx. 1968. Friedman M. Surgical management of the superior thyroid pole. Otolaryngol Clin North Am. 1986. Wang C, et al. Vascular supply of the infrahyoid muscles and its surgical relevance. Surg Radiol Anat.
Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes:
The SOUND Randomized Clinical Trial. Gentilini et al. JAMA Oncol. 2023 Sep 21:e233759. doi: 10.1001/jamaoncol.2023.3759
The SOUND trial that was published in JAMA Oncology concluded:
That patients with small breast cancer (less than 2 cm) and sonographically normal appearing lymph nodes:
Can be safely spared any axillary surgery:
Whenever the lack of pathological information does not affect the postoperative treatment plan
This study was designed to evaluate whether omission of sentinel lymph node (SLN) surgery in patients with negative axillary ultrasound:
Was noninferior to SLN surgery in terms of 5 year distant disease free survival
While this trial is unlikely to change practice immediately:
It is a thought provoking study that will likely generate multidisciplinary discussion
Phase III Randomized Controlled Trial:
Conducted at 18 European hospitals from 2012 to 2017:
Italy, Spain, Switzerland, and Chile:
Recruitment Feb 6, 2012 – Jun 30, 2017
Enrolled patients with invasive breast cancer up to 2 cm, cN0, planning for breast conserving surgery (BCT) and adjuvant radiation therapy (XRT) who had an axillary US showing no LN involvement on imaging:
If doubtful – FNA performed and had to be negative:
1406 negative AUS, 57 with negative FNA
Patients were randomized to SLN surgery vs no axillary surgery
Analysis cohort:
1405 women:
708 SLN
697 no axillary surgery
Median age 60
Tumor size 1.1 (IQR 0.8-1.5cm)
ER+ / Her2- disease in 87.8%
In the SLN group:
13.7% had positive nodes on SLN:
5.1% macrometases
8.6% micrometastases
2.0% had ≥ 2 positive SLNs, 0.6% had pN2 disease
Recommended adjuvant systemic therapy and radiotherapy were similar in the two groups:
20.1% of SLN group and 17.5% of no axillary surgery group received chemotherapy
98.0% of SLN group and 97.6% of no axillary surgery received radiation
83.3% (593 pts) vs 81.1% (565 pts) had whole breast radiation over 3 to 5 weeks
10.7% (76 pts) vs 10.8% (75 pts) had partial breast radiotherapy
3.4% (24 pts) vs 5.6% (39 pts) had intraoperative boost of ELIOT (12 Gy) followed by a hypofractionated course of whole-breast radiotherapy (37.05 Gy in 13 fractions)
The study authors concluded that patients with patients with small breast cancer with sonographically normal appearing lymph nodes:
Can be safely spared any axillary surgery:
Whenever the lack of pathological information does not affect the postoperative treatment plan
This study provides further data:
Supporting that axillary sentinel lymph node surgery does not provide therapeutic benefit
In the no axillary surgery group:
The cumulative incidence of lymph node recurrences in the axilla was very low:
0.4% at 5 years:
Despite a 13.7% rate of nodal involvement in the SLNB group
However, SLN surgery likely still has a role in certain patients for staging to guide adjuvant therapies:
In particular in young patients:
Where chemotherapy is associated with survival benefit for node positive disease (Rx-Ponder patient)
Furthermore, while adjuvant treatment recommendations in terms of rate of chemotherapy was similar between the two groups:
Identification of nodal positivity in ER+ breast cancer:
Also influences treatment options in terms of:
CDK4/6 inhibitor eligibility as well as consideration of extended endocrine therapy (to 10 years)
Many patients are interested in potential for omission of radiation therapy:
The trial required radiation, with 90% of patients having whole breast radiation and 10% partial breast radiation
Some of the patients in this trial with small breast cancers aged > 65 would be candidates for consideration of omission of radiation
This creates a dilemma regarding de-escalating axillary surgery leading to potential escalation of adjuvant radiation
It should be noted that tumor grade was not an inclusion / exclusion factor:
However, 18% had grade 3 disease
Patients with grade 3 disease have higher likelihood of nodal positivity:
Should omission of SLN surgery be limited to grade 1 and 2 disease at outset
Especially as grade 3 disease with 1 to 3 positive nodes:
Would make patients eligible for CDK4/6 inhibitor
Genomic scores were not included on this trial:
Most patients with ER+ / Her2- disease (with tumors > 1 cm in size) would be considered for genomic testing to guide systemic treatment recommendations
In summary:
Multidisciplinary discussion will be important before implementing any changes in practice as a result of the SOUND trial
I look forward to additional data from several other trials evaluating this question over the upcoming years:
Suggested that completion axillary dissection can be avoided in patients with:
cT1 to cT2, cN0 breast cancer with sentinel lymph node (SLN) metastasis:
Provided that systemic therapy and whole-breast irradiation (WBI):
Are incorporated into the treatment strategy for early-stage breast cancer following breast-conserving surgery (BCS)
This trial enrolled:
Clinically node-negative patients with:
Tumors less than 5 cm in size and with 1 to 2 positive SLNs by hematoxylin and eosin staining who were treated with BCS and planned WBI
Patients were randomized to:
SLN biopsy alone vs. axillary lymph node dissection (ALND)
The 10-year:
Overall survival was similar in the SLNB only group compared to the ALND group:
86.3% vs. 83.6%, p = 0.72
Disease-free survivalwas similar in the SLNB only group compared to the ALND group:
80.2% and 78.2%
In patients treated with ALND:
27% had additional non-SLN disease found at the time of ALND:
Suggesting that patients treated with SLNB alone would have a similar disease burden:
Yet, nodal recurrence rates were similar between the SLNB and ALND groups at 10 years:
1.5% vs. 0.5%, p = 0.13
Suggesting that systemic therapy and radiation therapy:
Provide adequate local control in patients with limited disease burden in the axilla
The AMAROS trial:
Is a phase III non-inferiority study:
Comparing ALND with axillary radiation therapy in patients with:
Clinical T1 / T2 N0 breast cancer with a positive sentinel node
The trial showed low 5-year rates of regional recurrence:
In the ALND and axillary radiation therapy groups:
0.43% vs 1.19%, respectively
But the risk of patient perceived (subjective) or measured (objective) lymphedema:
Was twice as high in the ALND arm compared to the radiation arm:
Subjective
23% vs. 11% after 5 years of follow-up
Objective:
13% vs. 5% after 5 years of follow-up
The ACOSOG Z0010 trial:
Evaluates the incidence and impact of SLN and bone marrow micro-metastases on patients with early-stage breast cancer treated with BCS and radiation
It demonstrated that:
Identification of occult disease in the SNs with immunohistochemistry was not associated with survival
References:
Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 Randomized Trial. Ann Surg. 2010;252(3):426-432.Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227-1232.Rutgers EJ, Donker M, Straver ME. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROS trial (10981/22023). J Clin Oncol. 2013;31 (suppl; abstr LBA1001). Available at: http://meetinglibrary.asco.org/content/109779-132. Accessed November 7, 2013.Straver ME, Meijnen P, van Tienhoven G, et al. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010;17:1854-1861.
Hunt KK, Ballman KV, McCall LM, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012;256:428-436.
General morbidity data and reviews echo this principle
Field/Dose (typical in AMAROS):
Axilla levels I to III ± SCV, ~ 50 Gy in conventional fractions; most modern clinics use tangents / high tangents plus nodal fields as indicated. (Protocol details in trial reports.)
Bottom line:
ART = ALND for control, with less arm morbidity:
So when axillary therapy is needed after a positive SLN:
In 38% (16 / 42) of clinically node-negative but pathologically node-positive axillae:
The sentinel node was the only involved node:
Limited disease that a blind sample / low-level dissection might have missed PubMed
Anatomic insight:
Among the last 54 mapped cases:
10 had level II-only metastases:
Underscoring why targeted mapping can outperform low-level sampling PubMed
Why it mattered?
Provided the first clinical proof-of-concept in breast cancer that a mapped SLN can accurately stage the axilla with far less surgery:
Laying the groundwork for later multicenter validation (Krag 1998) and definitive RCTs (NSABP B-32, ACOSOG Z0011) that enabled omission of routine ALND in properly selected patients PubMed
Practical pearls / caveats:
Learning curve is real:
Early experience showed lower identification and some false-negatives
Performance improved to perfect concordance in later cases
Training and standardized technique are crucial PubMed
Technique used here was blue dye alone (pre-radioisotope era):
Subsequent adoption of radiotracer (± dye) further raised identification and lowered FNR, but the 1994 study established the principle